2016
PWM
2022
EPR
2025
FSSAI rPET
2030
Pharma 30B
PCR Usage Growth
2030 rPET Index
Key Insight
PCR opportunity driven by regulatory push and supply-demand gap. ACG positioned to capture premium market.
PCR Value Chain Pipeline
Competitive Positioning Matrix
Pharma MNC Exporter
- • Compliance-driven
- • Pays premium
Domestic Generics
- • Cost-sensitive
- • Adoption if offset
Hospitals/NGOs
- • Reputation-driven
- • Prefer sustainable
Market Gap Identified
No player offers pharma-grade sustainable blisters. ACG can lead with PCR integration.
Risks
- • Regulatory delays
- • Barrier parity issues
- • PCR premium 20-30%
- • Limited pharma-grade PCR
Dependencies
- • Govt incentives
- • UFlex/Banyan partnerships
- • Pharma pilots
- • Mono-PET validation
Success Factors
- • Mono-material blisters
- • Early dossiers
- • Closed-loop pilots
- • Cost parity 2030
4P Strategy
Product
GreenBlister line
Price
Value + EPR offsets
Place
Tier-1 hubs + export
Promotion
ESG pilots + white papers
12-Month Roadmap
Q1-Q2
Partners + lab tests
Q2-Q3
Line trials
Q3-Q4
Dossier + pilots + branding
# Pilots
PCR %
Cost Gap
EPR Savings
Dossier Status
ACG 3C Strategy
Compliance + Collaboration + Cost Parity